Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?

A. Grohová, K. Dáňová, R. Špíšek, L. Palová-Jelínková,

. 2019 ; 10 (-) : 79. [pub] 20190205

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006565

Diabetes mellitus is characterized by long standing hyperglycemia leading to numerous life-threatening complications. For type 1 diabetes mellitus, resulting from selective destruction of insulin producing cells by exaggerated immune reaction, the only effective therapy remains exogenous insulin administration. Despite accurate compliance to treatment of certain patients, transient episodes of hyperglycemia cannot be completely eliminated by this symptomatic treatment. Novel immunotherapeutic approaches based on tolerogenic dendritic cells, T regulatory cells and mesenchymal stem cells (MSCs) have been tested in clinical trials, endeavoring to directly modulate the autoimmune destruction process in pancreas. However, hyperglycemia itself affects the immune system and the final efficacy of cell-based immunotherapies could be affected by the different glycemic control of enrolled patients. The present review explores the impact of hyperglycemia on immune cells while providing greater insight into the molecular mechanisms of high glucose action and subsequent metabolic reprogramming of different immune cells. Furthermore, over-production of mitochondrial reactive oxygen species, formation of advanced glycation end products as a consequence of hyperglycemia and their downstream signalization in immune cells are also discussed. Since hyperglycemia in patients with type 1 diabetes mellitus might have an impact on immune-interventional treatment, the maintenance of a tight glucose control seems to be beneficial in patients considered for cell-based therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006565
003      
CZ-PrNML
005      
20200526100534.0
007      
ta
008      
200511s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2019.00079 $2 doi
035    __
$a (PubMed)30804929
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Grohová, Anna $u SOTIO a.s., Prague, Czechia. Department of Immunology, Second Faculty of Medicine, University Hospital Motol, Charles University in Prague, Prague, Czechia. Department of Pediatrics, Charles University in Prague, Second Faculty of Medicine, University Hospital Motol, Prague, Czechia.
245    10
$a Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account? / $c A. Grohová, K. Dáňová, R. Špíšek, L. Palová-Jelínková,
520    9_
$a Diabetes mellitus is characterized by long standing hyperglycemia leading to numerous life-threatening complications. For type 1 diabetes mellitus, resulting from selective destruction of insulin producing cells by exaggerated immune reaction, the only effective therapy remains exogenous insulin administration. Despite accurate compliance to treatment of certain patients, transient episodes of hyperglycemia cannot be completely eliminated by this symptomatic treatment. Novel immunotherapeutic approaches based on tolerogenic dendritic cells, T regulatory cells and mesenchymal stem cells (MSCs) have been tested in clinical trials, endeavoring to directly modulate the autoimmune destruction process in pancreas. However, hyperglycemia itself affects the immune system and the final efficacy of cell-based immunotherapies could be affected by the different glycemic control of enrolled patients. The present review explores the impact of hyperglycemia on immune cells while providing greater insight into the molecular mechanisms of high glucose action and subsequent metabolic reprogramming of different immune cells. Furthermore, over-production of mitochondrial reactive oxygen species, formation of advanced glycation end products as a consequence of hyperglycemia and their downstream signalization in immune cells are also discussed. Since hyperglycemia in patients with type 1 diabetes mellitus might have an impact on immune-interventional treatment, the maintenance of a tight glucose control seems to be beneficial in patients considered for cell-based therapy.
650    _2
$a zvířata $7 D000818
650    _2
$a přeprogramování buněk $7 D065150
650    _2
$a klinické zkoušky jako téma $7 D002986
650    _2
$a dendritické buňky $x imunologie $x metabolismus $x transplantace $7 D003713
650    _2
$a diabetes mellitus 1. typu $x imunologie $7 D003922
650    _2
$a lidé $7 D006801
650    _2
$a hyperglykemie $x imunologie $7 D006943
650    _2
$a imunologická tolerance $x účinky léků $7 D007108
650    _2
$a imunoterapie adoptivní $x metody $7 D016219
650    _2
$a transplantace mezenchymálních kmenových buněk $7 D045164
650    _2
$a mezenchymální kmenové buňky $x imunologie $7 D059630
650    _2
$a mitochondrie $x metabolismus $7 D008928
650    _2
$a monitorování fyziologických funkcí $7 D008991
650    _2
$a reaktivní formy kyslíku $x metabolismus $7 D017382
650    _2
$a regulační T-lymfocyty $x imunologie $x transplantace $7 D050378
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Dáňová, Klára $u SOTIO a.s., Prague, Czechia. Department of Immunology, Second Faculty of Medicine, University Hospital Motol, Charles University in Prague, Prague, Czechia.
700    1_
$a Špíšek, Radek $u SOTIO a.s., Prague, Czechia. Department of Immunology, Second Faculty of Medicine, University Hospital Motol, Charles University in Prague, Prague, Czechia.
700    1_
$a Palová-Jelínková, Lenka $u SOTIO a.s., Prague, Czechia. Department of Immunology, Second Faculty of Medicine, University Hospital Motol, Charles University in Prague, Prague, Czechia.
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 10, č. - (2019), s. 79
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30804929 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526100530 $b ABA008
999    __
$a ok $b bmc $g 1525423 $s 1096621
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 10 $c - $d 79 $e 20190205 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...